Title |
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
|
---|---|
Published in |
BMC Cancer, February 2018
|
DOI | 10.1186/s12885-018-4116-0 |
Pubmed ID | |
Authors |
Xiao-Dong Jiao, Chunming Ding, Yuan-Sheng Zang, Guanzhen Yu |
Abstract |
Gastric cancer patients with widespread metastasis, especially meningeal metastases, have an extremely prognosis and limited therapeutic choices. We reported the case of a 39-year-old male patient with HER2-positive gastric cancer with bone and meningeal metastases. He presented with multiple bone metastases and received 3 cycles of docetaxel plus S1. However, he complained with headache and imaging examinations revealed leptomeningeal carcinomatosis. FISH revealed that tumor cells in the cerebrospinal fluid were HER-positive. Herceptin was added to the regimen, but the symptoms were not relieved, the patient suffered from dizziness and nausea. The chemotherapy regimen was switched d to lapatinib (orally at 1250 mg/day, every day), capecitabine (orally at 1000 mg/m2, bid for 2 weeks, followed by a 1-week rest interval, as 1 cycle) and Herceptin (390 mg/3 weeks). After 3 weeks of the new treatment, all the symptoms relieved. The clinical complete response was maintained for 3 months. Lapatinib/Capecitabine combination therapy is an alternative treatment strategy for leptomeningeal carcinomatosis of HER2-positive gastric cancer in which trastuzumab and/or chemotherapy essentially has no effect. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 34 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 18% |
Student > Doctoral Student | 3 | 9% |
Student > Postgraduate | 3 | 9% |
Researcher | 3 | 9% |
Student > Master | 2 | 6% |
Other | 4 | 12% |
Unknown | 13 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 26% |
Nursing and Health Professions | 4 | 12% |
Biochemistry, Genetics and Molecular Biology | 3 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Psychology | 1 | 3% |
Other | 3 | 9% |
Unknown | 12 | 35% |